

Patel AH, Dave RM. Formulation and evaluation of sustained release in situ ophthalmic gel of neomycin sulphate. *Bull. Pharm. Res.* 2015;5(1):1-5.

References (13):

1. Basarkar GD, Shirsath GN, Patil SB. Development of microspheres containing diclofenac diethylamine as sustained release topical formulation. *Bull. Pharm. Res.* 2013;3(1):14-22.
<http://www.appconnect.in/wp-content/uploads/2011/03/ReprintBPR0662.pdf>
2. Chitra K, Srinath N, Bhimavarapu RD, Gowthami N, Meda H, Kanikanti D, Anne M. Development and *in vitro* evaluation of sustained release matrix tablets of salbutamol sulphate using hydrophilic and hydrophobic polymers. *Bull. Pharm. Res.* 2012;2(3):112-7.
<http://www.appconnect.in/wp-content/uploads/2013/04/ReprintBPR054.pdf>
3. Gupta S, Vyas SP. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. *Sci. Pharm.* 2010;78(4):959-76.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007614/>
4. Indian Pharmacopoeia, 6th Edition, Indian Pharmacopoeia Commission: Ghaziabad, India; 2010; Vol. 2, 725.
5. Lee VHL, Robinson JR. Topical ocular drug delivery: Recent developments and future challenges. *J. Ocul. Pharmacol. Therap.* 1986;2(1):67-108.
<http://www.ncbi.nlm.nih.gov/pubmed/3332284>
6. Mandal S, Thimmasetty MK, Prabhushankar G, Geetha M. Formulation and evaluation of an *in situ* gel-forming ophthalmic formulation of moxifloxacin hydrochloride. *Int. J. Pharm. Investig.* 2012;2(2):78-82.
<http://www.ncbi.nlm.nih.gov/pubmed/23119236>
7. Mishra DK, Jain DK. Formulation and evaluation of valsartan sustained release matrix tablets. *Bull. Pharm. Res.* 2014;4(2):81-5.
<http://journal.appconnect.in/wp-content/uploads/2014/05/ReprintBPR094.pdf>
8. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. *Int. J. Pharm.* 2001;229(1-2):29-36.
<http://www.sciencedirect.com/science/article/pii/S0378517301008250>
9. Mohanambal E, Arun K, Abdul Hasan Sathali A. Formulation and evaluation of pH triggered *in situ* gelling system of levofloxacin. *Indian J. Pharm. Educ. Res.* 2011;45(1):58-64.
http://www.infectweb.com/cgi-bin/search.cgi?detailed_search=true&field0=serial_no&keyword0=&index1852=on

10. Nagpal N, Arora M, Rahar S, Rageeb M, Swami G. Formulation and evaluation of sustained release floating microballoons of ketorolac trometamol. *Bull. Pharm. Res.* 2014;4(2):86-93.
<http://journal.appconnect.in/wp-content/uploads/2014/05/ReprintBPR095.pdf>
11. Qi H, Chen W, Huang C, Li L, Chen C, Li W, Wu C. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. *Int. J. Pharm.* 2007;337(1-2):178-87.
<http://www.ncbi.nlm.nih.gov/pubmed/17254725>
12. Robinson JC. Ocular anatomy and physiology relevant to ocular drug delivery, In: A. K. Mitra (ed.). *Ophthalmic Drug Delivery Systems*, Marcel Dekker: New York, 1993; 29-57.
13. Sasaki H, Yamamura K, Nishida K, Nakamura J, Ichikawa M. Delivery of drugs to the eye by topical application. *Prog. Ret. Eye Res.* 1996;15(2):583-620.
<http://www.sciencedirect.com/science/article/pii/1350946296000146?np=y>

